

CONVERSATORIO
GLAUCOMA

SEPTIEMBRE 13 DE 2011

MEDICAMENTOS ACTUALES

- Timolol + dorzolamida: Cosopt, Dorzopt, Glaucotensil - t, Dortim
- Timolol + brinzolamida: Azarga
- Timolol + Brimonidina: Combigan
- Brimonidina: Alpghagan y Alphagan-p
- Timolol+Brimondina+Dorzolamida:KrytanteK

MEDICAMENTOS ACTUALES

- Prostaglandínicos y derivados:
- Latanoprost: Xalatan, Latanox, Louten, Gaap
- Travoprost: Travatan
- Bimatoprost : lumigan y Lumigan R- C

CADA MEDICAMENTO TIENES SU NICHO

- H.CLINICA 552954
- H.CLINICA 504144
- H,CLINICA 92507278
- H.CLINICA 43469155





Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension

L. JAY KATZ, JOHN S. COHEN, AMY L. BATOOSINGH, CARLOS FELIX, VINCENT SHU, AND RHETT M. SCHIFFMAN

Ophthalmol 2010;149:661–671. © 2010 by Elsevier Inc. All rights reserved

- **CONCLUSIONS: Bimatoprost 0.01% was equivalent to bimatoprost 0.03% in lowering IOP throughout 12 months of treatment and demonstrated improved tolerability, including less frequent and severe conjunctival hyperemia. Bimatoprost 0.01% demonstrated a better**
- **“La hiperemia es importante para la adherencia”, orden hasta ahora, de menor a mayor grado de hiperemia: Latanoprost- Travoprost- Bimatoprost**

- METHODS
- **STUDY DESIGN:** This prospective, randomized, multi-center (32 sites in the United States), double-masked, parallel-group, phase 3 study compared bimatoprost 0.01%, bimatoprost 0.0125%, and bimatoprost 0.03% in patients with glaucoma or OHT. The investigators and sites that took part in the study are listed in the Acknowledgments. The study was conducted in accordance with applicable Good Clinical Practice regulations and guidelines.